Avoiding, Treating & Curing Cancer | Dr. Alex Marson
Summary
Dr. Alex Marson, a physician-scientist at UCSF and the Gladstone Institutes, joins Andrew Huberman to discuss the biology of the immune system, the mechanisms underlying cancer development, and emerging therapies that are transforming oncology. The conversation spans practical lifestyle factors that increase or decrease cancer risk, and cutting-edge technologies including CAR-T cell therapy and CRISPR gene editing that are moving from science fiction to clinical reality.
Key Takeaways
- Cancer is fundamentally a genetic disease — mutations accumulate in cells over time, causing them to lose normal regulation and divide uncontrollably.
- The biggest evidence-based cancer risk factors are smoking, excessive UV exposure, and pesticide/chemical mutagen exposure; food dyes and charred meat carry far less certain risk.
- Everyone with a family history of cancer should consider testing for BRCA mutations, which dramatically elevate individual cancer risk even though they represent a minority of all cancers.
- Checkpoint inhibitor immunotherapy (e.g., PD-1, CTLA-4 blockers) has been transformative, particularly for melanoma — including the well-publicized case of Jimmy Carter’s brain metastases.
- CAR-T cell therapy — genetically engineering a patient’s own T-cells to target cancer — has produced remarkable cures in pediatric and adult leukemia/lymphoma patients.
- CRISPR-Cas9 now enables precise, programmable gene editing of T-cells, opening a new era of engineered immunotherapies currently in clinical trials.
- Obesity and high-fat diets appear to qualitatively alter immune responses, not just reduce immune quantity — and may cause immunotherapy drugs to work differently or less effectively.
- Cancer risk increases with age primarily because mutations accumulate over time across many cell divisions, making transformation more probable.
- You can do everything right and still develop cancer — it is a probabilistic disease, and individual outcomes should never be attributed to personal failure.
Detailed Notes
The Immune System: Core Architecture
Innate Immune System
- The first-alarm system, consisting of cells like dendritic cells and macrophages
- Recognizes generic patterns of foreign or damaged material
- Triggers release of signaling molecules (cytokines) that recruit adaptive immune cells
Adaptive Immune System
- Major players: T-cells and B-cells (types of lymphocytes)
- Each T-cell carries a unique, randomly generated T-cell receptor (TCR) on its surface
- TCR diversity is probabilistic — meaning the body carries T-cells capable of recognizing pathogens that don’t even exist yet
- B-cells produce antibodies through a similar random recombination process
The Thymus and T-Cell Education
- Thymus is the organ where T-cells undergo selection
- Positive selection: T-cells must have a functional receptor to survive
- Negative selection: T-cells that accidentally recognize the body’s own tissues are eliminated
- The thymus shrinks with age; its education of T-cells is most active in childhood
Autoimmunity
- Occurs when normal checks fail and T-cells or antibodies attack the body’s own tissues
- Examples:
- Joints → rheumatoid arthritis
- Insulin-producing pancreatic cells → type 1 diabetes
- Myelin in the brain → multiple sclerosis
- Therapeutic goal: targeted suppression of only the misdirected immune response, not blanket immunosuppression
Cancer Biology
What Cancer Is
- A genetic disease where mutations in a cell’s DNA cause it to lose normal growth regulation
- Cells begin dividing uncontrollably, acquiring further mutations over time
- Metastasis occurs when cancer cells spread from the original site to distant organs — driven by further evolutionary genetic changes in the tumor
How Mutations Accumulate
- Every cell division involves DNA replication, which is imperfect
- Most mutations are harmful to the cell and trigger programmed cell death (apoptosis)
- Occasionally a mutation confers a growth advantage — those daughter cells propagate the mutation
- A second or third “hit” may convert mildly abnormal cells into full-blown cancer
Cancer Risk Increases With Age
- Most cancers are diseases of later life because mutation accumulation is a time-dependent process
- Some cancers (e.g., certain childhood leukemias) peak early during developmental periods
Cancer Risk Factors
Well-Established Mutagens/Carcinogens
- Smoking — the largest preventable cause; chemicals in smoke directly damage lung cell DNA
- UV radiation — major risk factor for melanoma and skin cancers; sunburn is particularly damaging
- Pesticides — cancer rate spikes seen in agricultural regions suggest significant risk; understudied
- Workplace/lab chemical exposures — paints, thinners, solvents, and radioactive labels are real mutagens
- X-rays and ionizing radiation — necessary in clinical contexts, but low-dose repeated exposures (e.g., frequent flying) may confer cumulative risk
Genetic Predisposition
- BRCA mutation (BRCA1/BRCA2) dramatically elevates lifetime risk of breast, ovarian, and other cancers
- Identified partly because men who developed breast cancer disproportionately carried it
- Testing is widely available and recommended for those with a family history of cancer
Areas of Uncertainty
- Charred/processed meats: Implicated in colorectal cancer risk, but nutritional study methodology is often confounded
- Food dyes: Animal data exist at very high doses; human relevance at typical dietary exposure is unclear
- Ultraprocessed foods: Likely harmful broadly, though mechanistic cancer data are incomplete
- Dr. Marson’s view: We are under-investing in rigorous human-relevant studies of environmental and dietary carcinogens
Cancer Immunotherapy
Checkpoint Inhibitors
- Cancer cells can “cloak” themselves by activating natural brakes on T-cells (via PD-1, CTLA-4 pathways)
- Drugs that block these brakes (checkpoint inhibitors) unleash existing T-cells against tumors
- Most celebrated success: melanoma — Jimmy Carter’s brain metastases resolved with checkpoint inhibitor treatment
- Now approved and used across multiple cancer types
- T-cells are extracted from a patient, genetically modified to express a chimeric antigen receptor (CAR) — an artificial receptor designed in a lab
- CARs are engineered to target specific proteins on cancer cells
- Modified T-cells are reinfused like a blood transfusion and programmed to hunt cancer
- Target example: CD19, a protein found on B-cell leukemias and lymphomas
- First pediatric patient: Emily Whitehead, age 8 in 2012, had exhausted all treatments for leukemia, received CAR-T cells at University of Pennsylvania — now in remission and attending UPenn pre-med
- Original delivery method used lentiviral vectors (modified HIV viruses) to insert the CAR gene
Limitations of Early CAR-T
- Lentiviral insertion is imprecise — DNA integrates randomly
- Works well for blood cancers (leukemia, lymphoma) but poorly for solid tumors (e.g., pancreatic, brain cancers)
- Solid tumor environments are immunosuppressive, resisting T-cell activity
CRISPR Gene Editing
Origins
- Discovered as a bacterial immune defense system against bacteriophage viruses
- Bacteria use CRISPR to scan DNA, recognize viral sequences, and cut them
- Jennifer Doudna and Emmanuelle Charpentier recognized this could be reprogrammed as a general gene-editing tool — awarded Nobel Prize
How CRISPR-Cas9 Works
- Cas9: a protein that acts as molecular scissors to cut DNA
- Guide RNA: a programmable RNA molecule that directs Cas9 to a specific DNA sequence
- The guide RNA can be designed to match any genomic target, ordered online, and delivered to cells within days
- Once a cut is made: you can delete genes, **dis